Pneumococcal infections and protection with vaccination in adult chronic lung diseases

KILINC, OGUZ; Ozhan, Mustafa Hikmet; Pullukçu, Hüsnü; akinci ozyurek, berna; Karadeniz, Gülistan; Saltoglu, Nese; ÖZLÜ, Tevfik; Sayiner, Abdullah; Ölmez, Ayşe

doi:10.5578/tt.70012

Pneumococcal infections and protection with vaccination in adult chronic lung diseases

Gülistan KARADENİZ, (İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Kliniği, İzmir, Türkiye)

Oğuz KILINÇ, (Dokuz Eylül Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İzmir, Türkiye)

Ayşe ÖLMEZ, (Pfizer İlaçları, Aşı Departmanı, İstanbul, Türkiye)

Mustafa OZHAN, (Ege Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İzmir, Türkiye)

Tevfik ÖZLÜ, (Karadeniz Teknik Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Berna AKINCI ÖZYÜREK, (Ankara Atatürk Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Kliniği, Ankara, Türkiye)

Hüsnü PULLUKÇU, (Ege Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, İzmir, Türkiye)

Neşe SALTOĞLU, (İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye)

Abdullah SAYINER (Ege Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İzmir, Türkiye)

Tüberküloz ve Toraks

2 0

Yıl: 2020 Cilt: 68 Sayı: 3 Sayfa Aralığı: 305 - 320 Metin Dili: İngilizce DOI: 10.5578/tt.70012 İndeks Tarihi: 09-06-2022

Pneumococcal infections and protection with vaccination in adult chronic lung diseases

Öz:

Pneumococcal infections are an important cause of mortality and morbidity in Chronic Lung Diseases. However, exacerbations, which make the treatment of diseases very difficult, and corticosteroids used during treatment carry a great risk of pneumococcal infection and adversely affect the treatment. The most rational way to reduce the negative impact of pneumococcal infections on the clinical and economic burden of Chronic Lung Diseases is vaccination of the risky population. Although, vaccination recommendations are well defined, recommended by national and international guidelines and are paid by health authorities, in Turkey, vaccination rates in adults with chronic lung disease is far below the expected. Since physicians are considered to be the most important and reliable resource that can guide their patients in vaccination, applying pneumococcal vaccination routinely in all patients with chronic lung diagnosis and making it a part of daily practice will greatly contribute to reducing the clinical and economic burden of pneumococcal infections in these patients. In this review, the effects of pneumococcal diseases on chronic lung diseases, the risk and clinical burden of pneumococcal diseases in chronic lung diseases are discussed in the light of guidelines and current literature, and the importance of protection from pneumonia in these patients is emphasized. In addition to general information and efficacy data about pneumococcal vaccines available in our country, application methods and access routes to vaccines are also described.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Huanga SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011; 29(18): 3398-412.
2. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014;1(1): ofu024
3. MacNee W. Acute exacerbations of COPD. Swiss Med Wkly 2003: 133: 247-57.
4. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117: 380-5.
5. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67(1): 71-9.
6. Said MA, Johnson HL, Nonyane BAS, Deloria-Knoll M, O’Brien KL, for the AGEDD Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013; 8(4): 60273.
7. Ozlu T, Bulbul Y, Aydin D, Tatar D, Kuyucu T, Erboy F, et al. Immunization status in chronic obstructive pulmonary disease: A multicenter study from Turkey. Ann Thorac Med 2019; 14: 75-82.
8. T.C. Sağlık Bakanlığı Risk Grubu Aşılamaları. Erişim Tarihi: Mart 2020 Available from: https://asirehberi.saglik.gov.tr/ genelgeler/risk-grubu-genelgesi.
9. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2020 Report. Erişim tarihi: Mart 2020 Available from: https://goldcopd.org/wp-content/uploads/2019/11/ GOLD-2020-REPORT-ver1.0wms.pdf.
10. Türkiye Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Uzmanlık Derneği Erişkin Bağışıklama Çalışma Grubu Erişkin Bağışıklama Rehberi 2019. Erişim Tarihi: Mart 2020 Available from: https://www.ekmud.org.tr/emek/rehberler/ 1-ekmud-rehberleri
11. Şenol E, Azap A, Erbay A, Alp-Çavuş S, Karakuş R, Acar A. Pneumococcal vaccine as one of the immunization coverage targets for adulthood vaccines: A consensus report of the study group for adult immunization of the Turkish society of clinical microbiology and infectious diseases. Klimik Derg 2018; 31(Suppl 1): 2-18.
12. Ozlu T, Bulbul Y, Alataş F, Arseven O, Coşkun AŞ, Çilli A ve ark. Türk Toraks Derneği erişkinlerde toplumda gelişen pnömoni tanı ve tedavi uzlaşı raporu. Turk Toraks Derg 2009; 10: 5-9.
13. Kocabaş A, Atış S, Çöplü L, Erdinç E, Ergan B, Gürgün A ve ark. Kronik obstrüktif akciğer hastalığı (KOAH) koruma, tanı ve tedavi raporu. Turk Toraks Derg 2014; 15 (Suppl 2): 1-11.
14. Türkiye İstatistik Kurumu. Ölüm nedenlerinin cinsiyete göre dağılımı (2009-2018). Erişim Tarihi: Mart 2020. Available from: http://www.tuik.gov.tr/PreTablo.do?alt_ id=1083.
15. Ozlü T, Bülbül Y, Özsu S. Ulusal verilerle toplum kökenli pnömoniler. Tuberk Toraks Derg 2007;55(2):191-212.
16. National Institute for Health and Care Excellence. Pneumonia in Adults: Diagnosis and Management [published December 3, 2014]. Erişim Tarihi: Mart 2020.
Available from: https://www.nice.org.uk/guidance/ cg191/resources/pneumonia-in-adults-diagnosis- and-management-35109868127173.
17. Gil-Prieto R, García-García L, Álvaro-Meca A, Méndez C, García A, de Miguel AG. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine. 2011; 29(3): 412-6.
18. Tabaru A, Ozden K, Yılmaz N, Akgün M. Results of treatment approach for acute exacerbation of COPD and community-acquired pneumonia before and after infection control committee.
19. File TM. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004; 117(Suppl 3A): 39-50.
20. Wyrwich KW, Yu H, Sato R, Strutton D, Powers JH. Community-acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older. Patient 2013; 6(2): 125-34.
21. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 Years: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2019; 68(46): 1069-75.
22. Curcio D, Cane A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis 2015; 37: 30-5.
23. Yıldırım İ, Shea KM, Pelton SI. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect Dis Clin N Am 2015; 29: 679-97.
24. Bello S, Menéndez R, Antoni T, Reyes S, Zalacain R, Capelastegui A, et al. Tobacco smoking increases the risk for death from Pneumococcal pneumonia. Chest 2014; 146(4): 1029-37.
25. Pelton SI, Shea KM, Farkouh RA, Strutton DR, Braun S, Jacob C, et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis 2015; 15: 470.
26. Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, et al. Pneumococcal epidemiology among us adults hospitalized for community- acquired pneumonia. Vaccine 2019; 37(25): 3352-61.
27. Ishiguro T, Takayanagi N, Yamaguchi S, Yamakawa H, Nakamoto K, Takaku Y, et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern Med 2013; 52(3): 317-24.
28. Köksal I, Ozlu T, Bayraktar O, Yılmaz G, Bülbül Y, Oztuna F, et al. Etiological agents of community-acquired pneumonia in adult patients in Turkey; a multicentric, cross-sectional study. Tuberk Toraks Derg 2010; 58(2): 119-27.
29. Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. Rethinking risk for pneumococcal disease in adults: the role of risk stacking. Open Forum Infect Dis 2015; 2(1): ofv020.
30. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the united states: incidence, epidemiology, and mortality. Clin Infect Dis 2017; 65(11): 1806-12.
31. Van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65(1): 17-24.
32. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The natural history of community- acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106(8): 1124- 33. 33. Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, et al. Serotype prevalence in adults hospitalized with pneumococcal noninvasive community-acquired pneumonia. Thorax 2012; 67(6): 540-5.
34. World Health Organization. Burden of COPD. Erişim Tarihi: Mart 2020. Available from: https://www.who.int/ respiratory/copd/burden/en.
35. World Health Organization. Top 10 causes of death. Erişim Tarihi: Mart 2020. Available from: https://www. who.int/en/news-room/fact-sheets/detail/the-top-10- causes-of-death
36. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786-96.
37. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-65.
38. Andreassen SL, Liaaen ED, Stenfors N, Henriksen AH. Impact of pneumonia on hospitalizations due to acute exacerbations of COPD. Clin Respir J 2014; 8(1): 93-9.
39. Sogaard M, Madsen M, Lokke A, Hilberg O, Sorensen HT, Thomsen RW. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis 2016; 11: 455- 65.
40. Restrepo M, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality inpatients with community acquired pneumonia. Eur Respir J 2006; 28: 346- 51.
41. Zvezdin B, Milutinov S, Kojicic M, Hadnadiev M, Hromis S, Markovic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. CHEST 2009; 136: 376-80.
42. Crim C, Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkinse C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34(3): 641-7.
43. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: A systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2012; 7: 587-95.
44. Obert J, Burgel PR. Pneumococcal infections: association with asthma and COPD. Med Mal Infect 2012; 42(5): 188-92.
45. Bardin PG, Fraenkel DJ, Sanderson G, Dorward M, Lau LCK, Johnston SL, et al. Amplified rhinovirus colds in atopic subjects. Clin Exp Allergy 1994; 24: 457-64.
46. Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004; 31: 377-81.
47. Message SD, Johnston SL. Host defense function of the airway epithelium in health and disease: clinical background. J Leukoc Biol 2004; 75: 5-17.
48. Arkwright PD, Patel L, Moran A, Haeney MR, Ewing CI, David TJ. Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine. Clin Exp Immunol 2000; 122: 16-9.
49. Juhn YJ, Kita H, Yawn BP, Boyce TG, Yoo KH, McGree ME, et al. Increased risk of serious peumococcal disease in patients with asthma. J Allergy Clin Immunol 2008; 122(4): 719-23.
50. Klemets P, Lyytikainen O, Ruutu P, Ollgren J, Kaijalainen T, Leinonen M, et al. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax 2010; 65: 698-702.
51. Baxter R, Yee A, Aukes L, Snow V, Fireman B, Atkinson B, et al. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine 2016; 34: 4293-7.
52. Visser SK, Bye P, Morgan L. Management of bronchiectasis in adults. Med J Aust 2018; 209(4): 177-83.
53. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142: 432-9.
54. Quint JK, Millett ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47: 186-93.
55. Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One 2013; 8(8): e71109.
56. Säynäjäkangas O, Keistinen T. A bronchiectatic patient’s risk of pneumonia and prognosis. Cent Eur J Public Health 2009; 17(4): 203-6.
57. Polsky D, Bonafede M, Suaya JA. Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults. BMC Health Serv Res 2012; 12: 379.
58. Koşar F, Alıcı DE, Hacibedel B, Arpınar Yiğitbaş B, Golabi P, Çuhadaroğlu Ç. Burden of community-acquired pneumonia in adults over 18 y of age. Hum Vaccin Immunother 2017; 13(7): 1673-80.
59. European Respiratory Society. Gibson G, Loddenkemper R, Sibille Y, Lundbäck Bo, eds. European Lung White Book: respiratory health and disease in Europe, 2013. Erişim Tarihi: Mart 2020. Available from: http://www.erswhitebook. org/chapters/.
60. European Respiratory Society. The economic burden of lung disease: European Lung White Book. Erişim Tarihi: Mart 2020. Available from: http://www.erswhitebook. org/chapters/.
61. Castiglia P. Recommendations for pneumococcal immünization outside routine childhood immünization programs in WesternEurope. Adv Ther 2014; 31(10): 1011-44.
62. Chavanet P. Pneumococcus infections: is the burden still as heavy? Med Mal Infect 2012; 42(4): 149-53.
63. Kim DK, Riley LE, Hunter P. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018. Ann Intern Med 2018; 168: 210-20.
64. Sings HL. Pneumococcal conjugate vaccine use in adults- Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine 2017; 35(40): 5406- 17.
65. Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T. Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis 2015; 34(1): 19-31.
66. Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: a systematic review and meta-analysis. Vaccine 2019; 37(8): 1021-9.
67. Taylan M. Pnömokok aşıları. Güncel Göğüs Hastalıkları Serisi 2014; 2(1): 98-105.
68. Özkan S, Ceyhan M. Ulusal Aşı Çalıştayı (27-29 Mart 2014, Ankara) Raporu. Ankara: Sağlık Bakanlığı ve Enfeksiyon Hastalıkları Derneği, 2014.
69. Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7: 919-28.
70. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201: 516-24.
71. Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 2012; 30: 4435-44.
72. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011; 52: 633-40.
73. Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal vaccination strategies. An update and perspective. Ann Am Thorac Soc 2016; 13(6): 933-44.
74. Papadatou I, Spoulou V. Pneumococcal vaccination in high-risk individuals: are we doing it right? Clin Vaccine Immunol 2016; 23(5): 388-95.
75. O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7(9): 597-606.
76. de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46(7): 1015-23.
77. Clutterbuck EA, Salt P, Oh S, Marchant A, Beverley P, Pollard AJ. The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology 2006; 119(3): 328-37.
78. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9(3): 213-20.
79. Siegrist CA. Vaccine immunology. In: Plotkin SA, Orenstein W, Offitt PA, (eds). Vaccines. 5th ed. Amsterdam, the Netherlands: Elsevier; 2008: 17-36.
80. 23 valan Polisakkarid Pnömokok Aşısı Kısa Ürün Bilgisi.
81. 13 valan Konjuge Pnömokok Aşısı Kısa Ürün Bilgisi.
82. Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hy
83. Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J Infect Dis 2010; 201: 525-33.
84. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96-103.
85. Rodriguez-Blanco T, Vila-Corcoles A, de Diego C, Ochoa- Gondar O, Valdivieso E, Bobe F, et al. Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years. Human Vaccines Immunother 2012; 8: 363-70.
86. Frenck RW, Gurtman A, Rubino J, Smith W, van Cleef M, Jayawardene D, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clinical and Vaccine Immunology. 2012; 19: 1296-303.
87. Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥ 65 years. Vaccine 2013; 31: 291-4.
88. Zhang YY, Tang XF, Du CH, Wang BB, Bi ZW, Dong BR. Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis. Hum Vaccin Immunother 2016; 12: 3056-64.
89. Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly 2015; 145: 14159.
90. Hugle T, Bircher A, Walker UA. Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet’s disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology (Oxford) 2012; 51: 761-2.
91. Bonten MJ, Huijts SM, Bolkenbass M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372(12): 1114-25.
92. Suaya JA, Jiang Q, Bonten M, Scott DA, Gruber WC, Webber C, et al. Post-hoc analysis of the 13-valent polysaccharide conjugate vaccine efficacy against vaccine-serotype pneumococcal community acquired pneumonia in at-risk older adults. Presented at: 10th international symposium on pneumococci & pneumococcal diseases; June 26-30 2016; Glasgow, Scotland. Poster #634.
93. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. Vaccine 2013; 31(35): 3577-84.
94. Bryant KA, Frenck R, Gurtman A, Rubino J, Treanor J, Thompson A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naïve to 23-valent pneumococcal polysaccharide vaccine. Vaccine 2015; 33: 5854-60.
95. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine- naive adults 60-64 years of age. Vaccine 2014; 32(20): 2364-74.
96. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J 2009; 180: 48-58.
97. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk - a systematic review and meta-analysis. PLoS One 2016; 11(1): e0146338.
98. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422.
99. Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine 2016; 34(13): 1540-50.
100. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis 2017; 17(3): 313-21.
101. Alfageme I, Vazquez R, Reyes N, Mun˜oz J, Ferna´ndez A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61(3): 189-95.
102. Htar MT, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One 2017; 12(5): e0177985.
103. Falkenhorst G, Remschmidt C, Harder T, Hummers- Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One 2017; 12(1): e0169368.
104. Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez- Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis 2006; 43(8): 1004-8.
105. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis 2017; 12: 3457-68.
106. Ipsos Healthcare. PneuVue. Adult Pneumonia Vaccine Understanding in Europe. A New View into Pneumonia Among Older Adults. Erişim Tarihi: Mart 2020. Available from: https://www.ipsos.com/sites/default/files/publication/ 1970-01/ipsos-healthcare-pneu-vue-report.pdf.
107. Ariñez-Fernandez MC, Carrasco-Garrido P, Garcia- Carballo M, Hernández-Barrera V, de Miguel AG, Jiménez- García R, et al. Determinants of pneumococcal vaccination among patients with chronic obstructive pulmonary disease in Spain. Hum Vaccin 2006; 2: 99-104.
108. Satman I, Akalin S, Cakir B, Altinel S; diaVAX Study Group. The effect of physicians’ awareness on influenza and pneumococcal vaccination rates and correlates of vaccination in patients with diabetes in Turkey: an epidemiological Study “diaVAX”. Hum Vaccin Immunother 2013; 9(12): 2618-26.
109. Ozsu S, Ucar E, Arslan Y, Maden E, Bilgic H. The Frequency of Influenza and Pneumococcal Vaccination in COPD. Solunum Dergisi 2011; 13(1): 21-5. Erişim Tarihi: Mart 2020. Available from: https://www.researchgate. net/profile/Yakup_Arslan2/publication/314216303_The_ Frequency_of_Influenza_and_Pneumococcal_ Vaccinat ion_in_COPD/l inks/5c640105a6fdccb- 608beb595/The-Frequency- o f-Influenza-and- Pneumococcal-Vaccination-in COPD.pdf?origin=publication_ detail
110. Demirdogen E, Uzaslan E, Sayıner A, Çilli A, Kılınç O, Coşkun AS, et al. Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation. Hum Vaccin Immunother 2017; 13(9): 2072-7.
111. Aka Aktürk Ü, Görek Dilektasli A, Sengül A, Musaffa Salepçi B, Oktay N, Düger M, et al. Influenza and pneumonia vaccination rates and factors affecting vaccination among patients with chronic obstructive pulmonary disease. Balkan Med J 2017; 34: 206-11.
112. Bülbül Y, Öztuna F, Gülsoy A, zlü T. Chronic obstructive pulmonary disease in Eastern black sea region: Characteristics of the disease and the frequency of influenza- pneumococcal vaccination. Turk Klin J Med Sci 2010; 30: 24-9.
113. Erer OF, Karadeniz G, Gazibaba D, Ürpek G, Yalnız E, Aktoğlu SÖ. Immunization in the chronic obstructive pulmonary disease: Can we have really done it? İzmir Göğüs Hastanesi Dergisi 2013; XXVII(1).
114. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Yetişkin aşılama. Erişim Tarihi: Mart 2020. Available from: https://asi.saglik.gov.tr/asi-kimlere-yapilir/liste/30-yeti% C5%9Fkin-a%C5%9F%C4%B1lama.html
115. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. ATS (Aşı Takip Sistemi). Erişim Tarihi: Mart 2020. Available from: https://asi.saglik.gov.tr/ats.html.

APA	Karadeniz G, KILINC O, Ölmez A, Ozhan M, ÖZLÜ T, akinci ozyurek b, Pullukçu H, Saltoglu N, Sayiner A (2020). Pneumococcal infections and protection with vaccination in adult chronic lung diseases. , 305 - 320. 10.5578/tt.70012
Chicago	Karadeniz Gülistan,KILINC OGUZ,Ölmez Ayşe,Ozhan Mustafa Hikmet,ÖZLÜ Tevfik,akinci ozyurek berna,Pullukçu Hüsnü,Saltoglu Nese,Sayiner Abdullah Pneumococcal infections and protection with vaccination in adult chronic lung diseases. (2020): 305 - 320. 10.5578/tt.70012
MLA	Karadeniz Gülistan,KILINC OGUZ,Ölmez Ayşe,Ozhan Mustafa Hikmet,ÖZLÜ Tevfik,akinci ozyurek berna,Pullukçu Hüsnü,Saltoglu Nese,Sayiner Abdullah Pneumococcal infections and protection with vaccination in adult chronic lung diseases. , 2020, ss.305 - 320. 10.5578/tt.70012
AMA	Karadeniz G,KILINC O,Ölmez A,Ozhan M,ÖZLÜ T,akinci ozyurek b,Pullukçu H,Saltoglu N,Sayiner A Pneumococcal infections and protection with vaccination in adult chronic lung diseases. . 2020; 305 - 320. 10.5578/tt.70012
Vancouver	Karadeniz G,KILINC O,Ölmez A,Ozhan M,ÖZLÜ T,akinci ozyurek b,Pullukçu H,Saltoglu N,Sayiner A Pneumococcal infections and protection with vaccination in adult chronic lung diseases. . 2020; 305 - 320. 10.5578/tt.70012
IEEE	Karadeniz G,KILINC O,Ölmez A,Ozhan M,ÖZLÜ T,akinci ozyurek b,Pullukçu H,Saltoglu N,Sayiner A "Pneumococcal infections and protection with vaccination in adult chronic lung diseases." , ss.305 - 320, 2020. 10.5578/tt.70012
ISNAD	Karadeniz, Gülistan vd. "Pneumococcal infections and protection with vaccination in adult chronic lung diseases". (2020), 305-320. https://doi.org/10.5578/tt.70012

APA	Karadeniz G, KILINC O, Ölmez A, Ozhan M, ÖZLÜ T, akinci ozyurek b, Pullukçu H, Saltoglu N, Sayiner A (2020). Pneumococcal infections and protection with vaccination in adult chronic lung diseases. Tüberküloz ve Toraks, 68(3), 305 - 320. 10.5578/tt.70012
Chicago	Karadeniz Gülistan,KILINC OGUZ,Ölmez Ayşe,Ozhan Mustafa Hikmet,ÖZLÜ Tevfik,akinci ozyurek berna,Pullukçu Hüsnü,Saltoglu Nese,Sayiner Abdullah Pneumococcal infections and protection with vaccination in adult chronic lung diseases. Tüberküloz ve Toraks 68, no.3 (2020): 305 - 320. 10.5578/tt.70012
MLA	Karadeniz Gülistan,KILINC OGUZ,Ölmez Ayşe,Ozhan Mustafa Hikmet,ÖZLÜ Tevfik,akinci ozyurek berna,Pullukçu Hüsnü,Saltoglu Nese,Sayiner Abdullah Pneumococcal infections and protection with vaccination in adult chronic lung diseases. Tüberküloz ve Toraks, vol.68, no.3, 2020, ss.305 - 320. 10.5578/tt.70012
AMA	Karadeniz G,KILINC O,Ölmez A,Ozhan M,ÖZLÜ T,akinci ozyurek b,Pullukçu H,Saltoglu N,Sayiner A Pneumococcal infections and protection with vaccination in adult chronic lung diseases. Tüberküloz ve Toraks. 2020; 68(3): 305 - 320. 10.5578/tt.70012
Vancouver	Karadeniz G,KILINC O,Ölmez A,Ozhan M,ÖZLÜ T,akinci ozyurek b,Pullukçu H,Saltoglu N,Sayiner A Pneumococcal infections and protection with vaccination in adult chronic lung diseases. Tüberküloz ve Toraks. 2020; 68(3): 305 - 320. 10.5578/tt.70012
IEEE	Karadeniz G,KILINC O,Ölmez A,Ozhan M,ÖZLÜ T,akinci ozyurek b,Pullukçu H,Saltoglu N,Sayiner A "Pneumococcal infections and protection with vaccination in adult chronic lung diseases." Tüberküloz ve Toraks, 68, ss.305 - 320, 2020. 10.5578/tt.70012
ISNAD	Karadeniz, Gülistan vd. "Pneumococcal infections and protection with vaccination in adult chronic lung diseases". Tüberküloz ve Toraks 68/3 (2020), 305-320. https://doi.org/10.5578/tt.70012